The role of mTOR inhibitors in neuroendocrine tumors

Andrew E. Hendifar, Sandy Liu, Edward Wolin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

There have been major developments in our understanding of the histopathological classification, genetics, molecular signaling pathways, and treatment of neuroendocrine tumors (NETs) over the last decade. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a promising target for well-differentiated NETs. The recent success of everolimus, an inhibitor of the mammalian target of rapamycin, is proof of principle that targeting this pathway will lead to improved outcomes in these patients. Novel therapies targeting angiogenesis, such as bevacizumab and sunitinib, are showing promise in NETs by improving progressionfree survival alone or in combination with mTOR inhibitors. There are an unprecedented number of ongoing clinical trials of innovative treatments for this disease, and the development of combination therapy will lead to better therapeutic outcomes.

Original languageEnglish (US)
Title of host publicationmTOR Inhibition for Cancer Therapy: Past, Present and Future
PublisherSpringer-Verlag France
Pages93-112
Number of pages20
ISBN (Electronic)9782817804927
ISBN (Print)9782817804910
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Sirolimus
Tumors
Phosphatidylinositol 3-Kinase
Therapeutics
Molecular Biology
Clinical Trials
Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hendifar, A. E., Liu, S., & Wolin, E. (2015). The role of mTOR inhibitors in neuroendocrine tumors. In mTOR Inhibition for Cancer Therapy: Past, Present and Future (pp. 93-112). Springer-Verlag France. https://doi.org/10.1007/978-2-8178-0492-7_5

The role of mTOR inhibitors in neuroendocrine tumors. / Hendifar, Andrew E.; Liu, Sandy; Wolin, Edward.

mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, 2015. p. 93-112.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hendifar, AE, Liu, S & Wolin, E 2015, The role of mTOR inhibitors in neuroendocrine tumors. in mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, pp. 93-112. https://doi.org/10.1007/978-2-8178-0492-7_5
Hendifar AE, Liu S, Wolin E. The role of mTOR inhibitors in neuroendocrine tumors. In mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France. 2015. p. 93-112 https://doi.org/10.1007/978-2-8178-0492-7_5
Hendifar, Andrew E. ; Liu, Sandy ; Wolin, Edward. / The role of mTOR inhibitors in neuroendocrine tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, 2015. pp. 93-112
@inbook{15cbeebcb7294760bd5756d907ff6602,
title = "The role of mTOR inhibitors in neuroendocrine tumors",
abstract = "There have been major developments in our understanding of the histopathological classification, genetics, molecular signaling pathways, and treatment of neuroendocrine tumors (NETs) over the last decade. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a promising target for well-differentiated NETs. The recent success of everolimus, an inhibitor of the mammalian target of rapamycin, is proof of principle that targeting this pathway will lead to improved outcomes in these patients. Novel therapies targeting angiogenesis, such as bevacizumab and sunitinib, are showing promise in NETs by improving progressionfree survival alone or in combination with mTOR inhibitors. There are an unprecedented number of ongoing clinical trials of innovative treatments for this disease, and the development of combination therapy will lead to better therapeutic outcomes.",
author = "Hendifar, {Andrew E.} and Sandy Liu and Edward Wolin",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-2-8178-0492-7_5",
language = "English (US)",
isbn = "9782817804910",
pages = "93--112",
booktitle = "mTOR Inhibition for Cancer Therapy: Past, Present and Future",
publisher = "Springer-Verlag France",

}

TY - CHAP

T1 - The role of mTOR inhibitors in neuroendocrine tumors

AU - Hendifar, Andrew E.

AU - Liu, Sandy

AU - Wolin, Edward

PY - 2015/1/1

Y1 - 2015/1/1

N2 - There have been major developments in our understanding of the histopathological classification, genetics, molecular signaling pathways, and treatment of neuroendocrine tumors (NETs) over the last decade. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a promising target for well-differentiated NETs. The recent success of everolimus, an inhibitor of the mammalian target of rapamycin, is proof of principle that targeting this pathway will lead to improved outcomes in these patients. Novel therapies targeting angiogenesis, such as bevacizumab and sunitinib, are showing promise in NETs by improving progressionfree survival alone or in combination with mTOR inhibitors. There are an unprecedented number of ongoing clinical trials of innovative treatments for this disease, and the development of combination therapy will lead to better therapeutic outcomes.

AB - There have been major developments in our understanding of the histopathological classification, genetics, molecular signaling pathways, and treatment of neuroendocrine tumors (NETs) over the last decade. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a promising target for well-differentiated NETs. The recent success of everolimus, an inhibitor of the mammalian target of rapamycin, is proof of principle that targeting this pathway will lead to improved outcomes in these patients. Novel therapies targeting angiogenesis, such as bevacizumab and sunitinib, are showing promise in NETs by improving progressionfree survival alone or in combination with mTOR inhibitors. There are an unprecedented number of ongoing clinical trials of innovative treatments for this disease, and the development of combination therapy will lead to better therapeutic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84957373919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957373919&partnerID=8YFLogxK

U2 - 10.1007/978-2-8178-0492-7_5

DO - 10.1007/978-2-8178-0492-7_5

M3 - Chapter

AN - SCOPUS:84957373919

SN - 9782817804910

SP - 93

EP - 112

BT - mTOR Inhibition for Cancer Therapy: Past, Present and Future

PB - Springer-Verlag France

ER -